The primary end point was the annualized rate of moderate or severe COPD exacerbations. An exacerbation was considered ... value was considered to indicate mild airflow obstruction; 50% or more ...

However, about half of the patients who use three different kinds of inhaled medications continue to experience COPD ...

Mepolizumab prolonged the time to first moderate/severe exacerbation. With mepolizumab vs. placebo, patients with COPD and type 2 inflammation experienced significantly fewer moderate/severe ...

The headline result from the MATINEE trial of IL-5 inhibitor Nucala (mepolizumab) in adults with COPD was a statistically significant reduction in the annualised rate of moderate or severe ...

COPD is a disease that damages your lungs over time. It may start with mild symptoms and then get ... which are flare-ups of severe symptoms. There are different grading systems, and one grading ...

All were mild ... (COPD) Lunsekimig is being explored in a broad population of asthma patients, regardless of their inflammation and severity status. The readout of the AIRCULES phase 2 study ...